by Richard Daverman, PhD
August 11, 2012 -- S*BIO of Singapore sold worldwide rights for a Phase III-ready HDAC inhibitor, intended for hematologic disorders, to MEI Pharma of San Diego; PharmaEngine of Taiwan acquired Asia-Pacific rights (including China) to a radiology-enhancing nanomedicine product from Nanobiotix S.A., a French company; Takeda Pharma officially opened its new headquarters for China clinical trials in Shanghai; Mindray Medical reported Q2 revenues climbed 23% to $267.8 million, handily beating expectations; and Biostar Pharma of Xianyang warned investors that its second quarter revenues will be 50% lower than Q1 because it shut down production of gelatin-based capsules. More details….
Stock Symbols: (NSDQ: MEIP) (TWO: 4162) (TSE: 4502) (NYSE: MR) (NSDQ: BSPM)
